Antibiotice Iaşi, one of Romania's main drug makers, is going to launch its first cancer treatment products next April and hopes to gain 10% of this market in the first two years.
"Antibiotice is getting ready to introduce 10 products for cancer treatment. There are big competitors in this field and this is the market boasting the biggest increases, of 35% in 2010. (...)," said Ioan Nani, general manager of Antibiotice Iaşi.
Sales of cancer drugs in October 2009-September 2010 reached 1.6bn RON (380m euros), namely 19.5% of the entire industry. The average price on this market stands at 547.3 RON (130 euros), according to Cegedim Romania.
Nani says the price at which these products will be launched cannot exceed 50 to 60% of the price of patent drugs, according to law. The price will also be lower than that of the generic drugs with which Antibiotice will compete, but Nani chose not to say by how much.
Antibiotice Iaşi, one of Romania's main drug makers, is going to launch its first cancer treatment products next April and hopes to gain 10% of this market in the first two years.
"Antibiotice is getting ready to introduce 10 products for cancer treatment. There are big competitors in this field and this is the market boasting the biggest increases, of 35% in 2010. (...)," said Ioan Nani, general manager of Antibiotice Iaşi.
Sales of cancer drugs in October 2009-September 2010 reached 1.6bn RON (380m euros), namely 19.5% of the entire industry. The average price on this market stands at 547.3 RON (130 euros), according to Cegedim Romania.
Nani says the price at which these products will be launched cannot exceed 50 to 60% of the price of patent drugs, according to law. The price will also be lower than that of the generic drugs with which Antibiotice will compete, but Nani chose not to say by how much.
